Stephen Chan

Summary

Affiliation: Nottingham City Hospital
Country: UK

Publications

  1. ncbi Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Stephen Chan
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Rd, Nottingham N65 1PB, United Kingdom
    J Clin Oncol 23:5314-22. 2005
  2. ncbi Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
    S Chan
    The City Hospital, Nottingham NG5 1PB, UK
    Br J Cancer 91:1420-4. 2004
  3. ncbi Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    A Mukherjee
    Nottingham University Hospitals NHS Trust City Hospital Campus, Department of Clinical Oncology, Nottingham, UK
    Expert Opin Pharmacother 8:2189-204. 2007
  4. ncbi 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation
    Kelly Huber
    School of Molecular Medical Sciences, Division of Clinical Oncology, University of Nottingham, Nottingham University Hospitals, City Hospital Campus, Nottingham NG5 1PB, United Kingdom
    Mol Cancer Ther 7:143-51. 2008
  5. ncbi A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer
    Stephen Chan
    Nottingham City Hospital, Nottingham, United Kingdom
    Semin Oncol 29:129-33. 2002
  6. ncbi Second-line chemotherapy for ovarian cancer
    Stephen Chan
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, NG5 1PB, Nottingham, UK
    Lancet Oncol 4:333-4. 2003
  7. ncbi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
    Michel Marty
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 23:4265-74. 2005
  8. ncbi Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
  9. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
  10. ncbi Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial
    Jean Marc Nabholtz
    University of California at Los Angeles, CA 90095 7077, USA
    J Clin Oncol 21:968-75. 2003

Collaborators

Detail Information

Publications12

  1. ncbi Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    Stephen Chan
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Rd, Nottingham N65 1PB, United Kingdom
    J Clin Oncol 23:5314-22. 2005
    ....
  2. ncbi Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
    S Chan
    The City Hospital, Nottingham NG5 1PB, UK
    Br J Cancer 91:1420-4. 2004
    ..The basic structure of the pathway was reviewed in this article, together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses many challenges to researchers...
  3. ncbi Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer
    A Mukherjee
    Nottingham University Hospitals NHS Trust City Hospital Campus, Department of Clinical Oncology, Nottingham, UK
    Expert Opin Pharmacother 8:2189-204. 2007
    ..The potential for combination and sequencing with other biological and cytotoxic agents is both exciting and challenging...
  4. ncbi 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation
    Kelly Huber
    School of Molecular Medical Sciences, Division of Clinical Oncology, University of Nottingham, Nottingham University Hospitals, City Hospital Campus, Nottingham NG5 1PB, United Kingdom
    Mol Cancer Ther 7:143-51. 2008
    ..These findings show that modulation of targets other than thioredoxin contribute to the effects of IV-2 on proliferating cells...
  5. ncbi A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer
    Stephen Chan
    Nottingham City Hospital, Nottingham, United Kingdom
    Semin Oncol 29:129-33. 2002
    ....
  6. ncbi Second-line chemotherapy for ovarian cancer
    Stephen Chan
    Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, NG5 1PB, Nottingham, UK
    Lancet Oncol 4:333-4. 2003
  7. ncbi Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
    Michel Marty
    Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 23:4265-74. 2005
    ..This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC)...
  8. ncbi Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial...
  9. ncbi Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    Charles E Geyer
    Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
    N Engl J Med 355:2733-43. 2006
    ..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...
  10. ncbi Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial
    Jean Marc Nabholtz
    University of California at Los Angeles, CA 90095 7077, USA
    J Clin Oncol 21:968-75. 2003
    ..This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT) with doxorubicin and cyclophosphamide (AC) as first-line chemotherapy (CT) in metastatic breast cancer (MBC)...
  11. ncbi Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
    Martine J Piccart-Gebhart
    Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    J Clin Oncol 26:1980-6. 2008
    ..This meta-analysis uses data from all relevant trials to detect any advantages of taxanes in terms of tumor response, progression-free survival (PFS), and survival...
  12. ncbi Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    Tomasz Burzykowski
    Hasselt University, Center for Statistics, Agoralaan, Bldg D, 3590 Diepenbeek, Belgium
    J Clin Oncol 26:1987-92. 2008
    ....